<DOC>
	<DOCNO>NCT00457639</DOCNO>
	<brief_summary>To evaluate efficacy safety cholic acid therapy treat lipodystrophy patient hepatic steatosis . This randomized , double-blind , placebo-controlled cross-over study .</brief_summary>
	<brief_title>Cholic Acid Hepatic Steatosis Lipodystrophy</brief_title>
	<detailed_description>Lipodystrophies rare disorder characterize selective loss adipose tissue predisposition develop insulin resistance associate metabolic complication dyslipidemia , diabetes mellitus hepatic steatosis . Nonalcoholic hepatic steatosis steatohepatitis cause excessive accumulation triglyceride hepatocytes , fact , common feature disorder . Often cause significant morbidity even mortality lipodystrophic patient , hepatic steatosis pose significant therapeutic challenge . Recent insight role primary bile acid , cholic acid chenodeoxycholic acid , endogenous ligand farnesoid X receptor ( FXR ) , regulate hepatic triglyceride homeostasis offer new treatment option hepatic steatosis . Cholic acid show inhibit hepatic triglyceride accumulation 50 % mouse model hepatic steatosis hypertriglyceridemia . Cholic acid previously use treat inborn error bile acid synthesis child without side effect . In study adult , cholic acid report well tolerate . Therefore , propose investigate potentially safe therapeutic option efficacy reduce hepatic steatosis patient lipodystrophies .</detailed_description>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Lipodystrophy</mesh_term>
	<mesh_term>Cholic Acids</mesh_term>
	<criteria>Patients lipodystrophies diagnose clinical criterion . Hepatic steatosis ( &gt; 5.6 % hepatic triglyceride content ) demonstrate 1H magnetic resonance spectroscopy . Age 670 year . Alcohol intake less 40 g per week . Laboratory histologic finding highly suggestive liver disease due cause nonalcoholic steatohepatitis , chronic viral hepatitis , autoimmune hepatitis , primary biliary cirrhosis , biliary obstruction genetic liver diseases Wilson 's disease , hemochromatosis alpha1antitrypsin deficiency . Treatment drug associate steatohepatitis , e.g. , corticosteroid , high dose estrogen , methotrexate , amiodarone , , sulfasalazine , oxacillin 6 month prior study . Decompensated liver disease evidence clinical feature hepatic failure ( variceal bleeding , ascites , hepatic encephalopathy etc . ) laboratory investigation ( prolonged prothrombin time , hypoalbuminemia , presence esophageal varix etc . ) Evidence hepatocellular carcinoma : alphafetoprotein level great 200 ng/ml and/or liver mass image study suggestive liver cancer . Use drug potentially decrease hepatic steatosis previous 3 month ; ursodeoxycholic acid , highdose vitamin E , betaine , acetylcysteine choline . Thiazolidinediones allow dose stable 3 month prior screen . Significant systemic major illness liver disease , congestive heart failure , cerebrovascular disease , respiratory failure , renal failure ( serum creatinine &gt; 2 mg/dL ) , acute pancreatitis , organ transplantation , serious psychiatric disease , malignancy , could interfere trial adequate follow . Acute medical illness preclude participation study . Known HIVinfected patient . Current substance abuse . Pregnant lactating woman . Hematocrit le 30 % . History weight loss past 3 month . Patients bile acid binding resin , cholestyramine , colestipol , colesevelam . Hypersensitivity intolerance CA component formulation</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>lipodystrophy</keyword>
</DOC>